Author: Grewal, Ekjot; Sutarjono, Bayu; Mohammed, Ibbad
Title: Angioedema, ACE inhibitor and COVID-19 Cord-id: 849bm17h Document date: 2020_9_9
ID: 849bm17h
Snippet: SARS-CoV-2, the virus responsible for COVID-19, binds to the ACE2 receptors. ACE2 is thought to counterbalance ACE in the renin-angiotensin system. While presently it is advised that patients should continue to use ACE inhibitors or angiotensin receptor blockers, questions still remain as to whether adverse effects are potentiated by the virus. Here, we report a case of a 57-year-old man, unknowingly with COVID-19, who presented to the emergency department with tongue swelling, shortness of brea
Document: SARS-CoV-2, the virus responsible for COVID-19, binds to the ACE2 receptors. ACE2 is thought to counterbalance ACE in the renin-angiotensin system. While presently it is advised that patients should continue to use ACE inhibitors or angiotensin receptor blockers, questions still remain as to whether adverse effects are potentiated by the virus. Here, we report a case of a 57-year-old man, unknowingly with COVID-19, who presented to the emergency department with tongue swelling, shortness of breath and difficulty in speaking following 4 months taking benazepril, an ACE inhibitor. Finally, we also describe possible pathways that exist for SARS-CoV-2 to interact with the mechanism behind angioedema.
Search related documents:
Co phrase search for related documents- ace inhibitor and acute ards respiratory distress syndrome: 1, 2, 3, 4
- ace inhibitor and admission prior: 1
- ace inhibitor and lung inflammation: 1
- ace inhibitor and lung injury: 1, 2, 3, 4
- ace inhibitor and lung kidney: 1, 2, 3
- ace inhibitor and lung kidney heart: 1, 2
Co phrase search for related documents, hyperlinks ordered by date